000140855 001__ 140855
000140855 005__ 20240229105118.0
000140855 0247_ $$2doi$$a10.1038/s41375-018-0268-9
000140855 0247_ $$2pmid$$apmid:30275528
000140855 0247_ $$2ISSN$$a0887-6924
000140855 0247_ $$2ISSN$$a1476-5551
000140855 0247_ $$2altmetric$$aaltmetric:49080910
000140855 037__ $$aDKFZ-2018-01610
000140855 041__ $$aeng
000140855 082__ $$a610
000140855 1001_ $$aBraess, Jan$$b0
000140855 245__ $$aSequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
000140855 260__ $$aLondon$$bSpringer Nature$$c2018
000140855 3367_ $$2DRIVER$$aarticle
000140855 3367_ $$2DataCite$$aOutput Types/Journal article
000140855 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1552642497_30639
000140855 3367_ $$2BibTeX$$aARTICLE
000140855 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140855 3367_ $$00$$2EndNote$$aJournal Article
000140855 520__ $$aDose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 = 'dose-dense') and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 = 'standard'). 387 evaluable patients were randomly assigned to S-HAM (N = 203) and to standard double induction (N = 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CRi) was not significantly different (P = 0.202) between S-HAM (77%) and double induction (72%). The median overall survival was 35 months after S-HAM and 25 months after double induction (P = 0.323). Duration of critical leukopenia was significantly reduced after S-HAM (median 29 days) versus double induction (median 44 days)-P < 0.001. This translated into a significantly shortened duration of hospitalization after S-HAM (median 37 days) as compared to standard induction (median 49 days)-P < 0.001. In conclusion, dose-dense induction therapy with the S-HAM regimen shows favorable trends but no significant differences in ORR and OS compared to standard double induction. S-HAM significantly shortens critical leukopenia and the duration of hospitalization by 2 weeks.
000140855 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000140855 588__ $$aDataset connected to CrossRef, PubMed,
000140855 7001_ $$aAmler, Susanne$$b1
000140855 7001_ $$aKreuzer, Karl-Anton$$b2
000140855 7001_ $$aSpiekermann, Karsten$$b3
000140855 7001_ $$aLindemann, Hans Walter$$b4
000140855 7001_ $$aLengfelder, Eva$$b5
000140855 7001_ $$aGraeven, Ullrich$$b6
000140855 7001_ $$aStaib, Peter$$b7
000140855 7001_ $$aLudwig, Wolf-Dieter$$b8
000140855 7001_ $$aBiersack, Harald$$b9
000140855 7001_ $$aKo, Yon-Dschun$$b10
000140855 7001_ $$aUppenkamp, Michael J$$b11
000140855 7001_ $$aDe Wit, Maike$$b12
000140855 7001_ $$aKorsten, Stefan$$b13
000140855 7001_ $$aPeceny, Rudolf$$b14
000140855 7001_ $$aGaska, Tobias$$b15
000140855 7001_ $$aSchiel, Xaver$$b16
000140855 7001_ $$aBehringer, Dirk M$$b17
000140855 7001_ $$aKiehl, Michael G$$b18
000140855 7001_ $$aZinngrebe, Bettina$$b19
000140855 7001_ $$aMeckenstock, Gerald$$b20
000140855 7001_ $$aRoemer, Eva$$b21
000140855 7001_ $$aMedgenberg, Dirk$$b22
000140855 7001_ $$aSpaeth-Schwalbe, Ernst$$b23
000140855 7001_ $$aMassenkeil, Gero$$b24
000140855 7001_ $$aHindahl, Heidrun$$b25
000140855 7001_ $$aSchwerdtfeger, Rainer$$b26
000140855 7001_ $$aTrenn, Guido$$b27
000140855 7001_ $$aSauerland, Cristina$$b28
000140855 7001_ $$aKoch, Raphael$$b29
000140855 7001_ $$0P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439$$aLablans, Martin$$b30$$udkfz
000140855 7001_ $$aFaldum, Andreas$$b31
000140855 7001_ $$aGörlich, Dennis$$b32
000140855 7001_ $$aBohlander, Stefan K$$b33
000140855 7001_ $$aSchneider, Stephanie$$b34
000140855 7001_ $$aDufour, Annika$$b35
000140855 7001_ $$aBuske, Christian$$b36
000140855 7001_ $$aFiegl, Michael$$b37
000140855 7001_ $$aSubklewe, Marion$$b38
000140855 7001_ $$aBraess, Birgit$$b39
000140855 7001_ $$aUnterhalt, Michael$$b40
000140855 7001_ $$aBaumgartner, Anja$$b41
000140855 7001_ $$aWörmann, Bernhard$$b42
000140855 7001_ $$aBeelen, Dietrich$$b43
000140855 7001_ $$aHiddemann, Wolfgang$$b44
000140855 7001_ $$aAML-CG$$b45$$eCollaboration Author
000140855 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/s41375-018-0268-9$$n12$$p2558-2572$$tLeukemia$$v32$$x1476-5551$$y2018
000140855 909CO $$ooai:inrepo02.dkfz.de:140855$$pVDB
000140855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000140855 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000140855 9141_ $$y2018
000140855 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000140855 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000140855 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2017
000140855 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000140855 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000140855 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000140855 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000140855 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000140855 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000140855 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000140855 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000140855 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000140855 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2017
000140855 9201_ $$0I:(DE-He78)G230-20160331$$kG230$$lMedizinische Informatik in der Translationalen Onkologie$$x0
000140855 980__ $$ajournal
000140855 980__ $$aVDB
000140855 980__ $$aI:(DE-He78)G230-20160331
000140855 980__ $$aUNRESTRICTED